Trial Profile
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Ralmitaront (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Roche
- 16 Jun 2023 This trial has been Completed in Croatia, According to European Clinical Trials Database record.
- 16 May 2023 Status changed from active, no longer recruiting to discontinued. This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.
- 11 May 2023 This trial has been discontinued in Poland and Spain (Ed Date: 04 Apr 2023) according to European Clinical Trials Database record.